“The field of immuno-oncology (I-O) continues to expand, as evidenced by the sheer number of different pathways and approaches we heard about at the meeting,” said Tom Lynch, chief scientific officer at Bristol Myers Squibb. “We’ve long believed that the future of I-O will rely on combinations of different agents to address a patient’s specific tumor biology. The more options we have to address cancer based on disease biology, the closer we are to realizing precision medicine for more patients.”
This approach continues to guide Bristol Myers Squibb’s robust early clinical development pipeline, with more than 15 oncology mechanisms in clinical studies targeting a variety of different pathways. At SITC, Bristol Myers Squibb had the opportunity to present the first disclosures for several new assets, including those targeting the OX40 and CSF1R immune pathways.